Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod Pathol. 2020;33(11):2156-2168.

Droesch C, Do MH, DeSancho M, Lee E-, Magro C, Harp J. Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19. JAMA Dermatol. 2020;156(9):1-3.

Humphries RM, Magnano P, Burnham CA, Bard JD, Dingle TC, Callan K, et al. Evaluation of Surrogate Tests for the Presence of -Mediated Methicillin Resistance in Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri. J Clin Microbiol. 2020;59(1).

Zviran A, Schulman RC, Shah M, Hill ST, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26(7):1114-1124.

Thoren KL, Avecilla ST, Klimek V, Goss C. A novel method for the laboratory workup of anaphylactic transfusion reactions in haptoglobin-deficient patients. Transfusion. 2020;60(4):682-687.

Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020;182(2):297-316.e27.

Bok S, Shin DY, Yallowitz AR, Eiseman M, Cung M, Xu R, et al. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I. Nat Commun. 2020;11(1):5704.

Satlin MJ, Goyal P, Magleby R, Maldarelli GA, Pham K, Kondo M, et al. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. PLoS One. 2020;15(7):e0236778.

Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, et al. Loss with Negative Status is Associated with Lethal Disease after Radical Prostatectomy. J Urol. 2020;203(2):344-350.

Sangiorgio VF, Geyer JT, Margolskee E, Al-Kawaaz M, Mathew S, Tam W, et al. Myeloid neoplasms with isolated del(5q) and V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features? Haematologica. 2020;105(6):e276-e279.